Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2001
Business Overview: Provider of enabling tools for drug discovery research, including protein/DNA analysis and ADMET screening. The company operates globally with significant presence in the U.S., U.K., and Germany.
Key Financial Metrics
| Metric (in thousands) | Q2 2001 | Q2 2000 | 6 Months 2001 | 6 Months 2000 |
|---|---|---|---|---|
| Total Revenue | $9,711 | $7,390 | $18,318 | $14,458 |
| Operating Income (Loss) | $(5,321) | $964 | $(4,802) | $2,149 |
| Net Loss | $(5,365) | $(62,317) | $(5,093) | $(66,684) |
| Cash and Equivalents (End of Period) | $31,182 | $2,145 | $31,182 | $2,145 |
| Operating Cash Flow (6 Months) | $2,668 | $1,177 | $2,668 | $1,177 |
| Long-Term Debt | $40 | $1 | $40 | $1 |
Margins (Q2 2001): Gross margin on product revenue was 49.4% (Cost of revenue was 50.6% of product revenue).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 31% in Q2 2001 and 27% for the six-month period compared to 2000. Growth was driven by organic expansion, new product introductions, and acquisitions.
- Acquisition Impact: The company completed three acquisitions in Q2 2001: Warner Instruments, Union Biometrica, and International Market Supply (IMS). These contributed to revenue but also resulted in significant non-cash charges.
- Non-Cash Charges: A $5.45 million charge for in-process research and development (IPR&D) was recorded in Q2 2001 related to the Union Biometrica and Warner Instruments acquisitions. This significantly impacted operating income.
- Stock Compensation: Stock compensation expense rose to $779,000 in Q2 2001 from $100,000 in Q2 2000, reflecting post-IPO equity plans and acquisition-related grants.
- Comparison to 2000 Loss: The net loss in Q2 2001 ($5.4M) is significantly lower than Q2 2000 ($62.3M). The 2000 loss was distorted by a $62.6 million non-cash warrant interest expense which was eliminated following the December 2000 IPO.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects cash proceeds from the IPO, existing cash ($31.2M), and operating cash flows to be sufficient to finance operations and capital expenditures for at least two years from June 30, 2001.
- Capital Needs: The company may need to raise additional capital to accelerate product development, expand sales, or make further acquisitions. Future equity raises could dilute existing shareholders.
- Legal Proceedings: Harvard University sued the company in December 2000 over trademark infringement regarding the names "Harvard Bioscience" and "Harvard Apparatus." In April 2001, the court denied a preliminary injunction but ordered the company not to use the name "Harvard" in crimson or a similar font. Management believes the claims are without merit and does not expect a material adverse effect.
- Accounting Changes: The company is assessing the impact of new FASB pronouncements (SFAS 141 and 142) regarding business combinations and goodwill, effective for acquisitions after June 30, 2001.
- Foreign Currency: Results are affected by exchange rate fluctuations. The company currently manages risk by matching assets and liabilities but may use hedging contracts in the future.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and success of integrating Union Biometrica and Warner Instruments, specifically regarding the commercialization of the $5.45M IPR&D assets.
- Trademark Litigation: Monitor the status of the Harvard University lawsuit and any potential costs or brand restrictions beyond the current court order.
- Recurring Revenue Quality: Assess the sustainability of the 31% revenue growth once the one-time impact of acquisitions is normalized.
- Cash Burn Rate: Confirm that the $31.2M cash balance remains sufficient given the company's plan to invest heavily in developing acquired technologies.
- Stock Compensation: Review future vesting schedules for the $3.7M in additional stock compensation expense noted for the remaining vesting life of acquisition-related options.